New Delhi: Dell Services has unveiled a cloud-based solution that delivers integrated clinical and financial systems for healthcare providers in India. This is a scalable and widely accessible to suit the unique needs of Indian healthcare providers.
Targeted at midsized hospitals, large hospital chains and clinic networks, the solution ensures that providers have instant access to uniform workflows and customized reports across entities and geographies. Through a centralized approach, the solution gives healthcare providers the ability to adopt automated workflows and business processes using a single-instance application, reducing operational complexity and dependencies on paper records. This not only prevents manual errors and time delays, but will also enhance decision making and improve the patient experience.
With this solution, end-users (physicians, nurses and back office staff) can access cloud-based applications and reports through the use of a simple conventional browser. The solution also allows users to remain connected via smart phones and other hand-held devices, ensuring secure and anytime, anywhere access to information.
Commenting on the role of cloud in enabling better healthcare outcomes, Dr Ashwin Naik, Founder and CEO, Vaatsalya, India's first hospital network focused on Tier II and Tier III towns said, "The healthcare industry in India is increasingly turning to IT adoption to improve patient outcomes. As hospitals and providers expand their operations with new referral centers, facilities, and acquisitions in new geographies, the need to access, integrate and connect these disparate systems is gaining importance. Cloud-based technology has the potential to addresses most of the IT-related issues -- access to the right information at the right time and operational efficiency, among others. More importantly it is affordable, scalable and flexible."
Dell is collaborating with Ubq Technologies and Ramco Systems to deliver an end-to-end proposition to providers. Ubq's Hospital Information System (HIS) solution, Medics, will serve as the front-end application for patient-centric activities and will integrate with Ramco ERP on Cloud to provide customers seamless enterprise-wide application on the cloud.
Delivered as a Software-as-a-Service (SaaS) model, the solution allows healthcare providers to quickly respond to increasing demands of infrastructure and storage, and train staff without huge capital investments and recurrent readiness costs.
"We are extending Dell's proven capabilities and global healthcare leadership to India and have brought in the best-of-breed combination of HIS and ERP to help providers achieve their goal of providing efficient, information-driven healthcare in an affordable way. We will continue to bring to India unique solutions that will allow healthcare providers to focus on their number one goal-- enhanced patient care," said Sid Nair, vice president and global general manager, Healthcare & Life Sciences, Dell Services. "The solution is truly one of a kind in terms of its capabilities, delivery model and pricing. We believe that this will be a game changer for the Indian healthcare industry, where hospitals are constrained by huge upfront capital investments, and higher cost of licensing, maintenance and support."
Success in my Habit
Sunday, March 30, 2014
ACC plans waste-heat recovery system at four plants
Mumbai: After commissioning its first waste-heat recovery plant at Gagal in Himachal Pradesh, ACC plans to replicate the success at its cement plants in Wadi (Karnataka), Jamul (Chhattisgarh), Kymore (Madhya Pradesh) and Chanda (Maharashtra) with an investment of about Rs. 360 crore.
The Gagal heat recovery plant, which produces 7.5 MW, achieved stabilisation last week. It is expected to reduce over 44,000 tonnes of carbon-dioxide emission a year. Gagal, faces shortage of power during winter, as hydro-power plants taper off generation due to snowing.
ACC invested Rs. 100 crore to set up the plant which is fitted with a turbine that can enhance power production to 9 MW as and when steam availability in the cement plant improves. ACC expects to recover the investment made in Gagal in four-and-a-half years with an annual saving of Rs. 22 crore.
KN Rao, Director (Energy and Environment), told Business Line the four cement plants where the heat recovery system would be installed over 3-4 years are capable of producing 30-32 MW in all, resulting in a savings of `90-100 crore a year.
Renewable energy status
“The Wadi cement plant has the world’s largest kiln and is capable of producing up to 9 MW. We are exploring various options of funding the projects,” he said.
The cement industry has urged the Government to give renewable energy status to waste-heat recovery plants. Most of the cement companies are power surplus as they have captive power plants. The surplus power produced through waste heat is sold at Rs. 2.30 a unit due to lack of renewable energy status.
A few cement plants buy grid power at Rs. 6.20 a unit, while the production cost of thermal power works out to Rs. 4.50-5 a unit. The industry with a cement production capacity of 350 million tonnes is capable of producing about 1,000 MW through waste heat recovery, said Rao. “The industry has to invest Rs. 12,000 crore to set up 1000 MW heat recovery plants. It would be viable only if the Government fixes a competitive price for the surplus power,” he said.
Apart for heat recovery plant, ACC has drawn an elaborate plan to bring down energy consumption by 5 per cent at its 10 plants by improving efficiency.
Energy saving measures
The company targets to take up energy saving measures, which call for low investment and early payback. For instance, Rao said installation of variable speed drive to control the speed of large motors used in the cement plant does not call for huge investment and the project can be completed in sa hort span, besides payback is less than a year.
The Gagal heat recovery plant, which produces 7.5 MW, achieved stabilisation last week. It is expected to reduce over 44,000 tonnes of carbon-dioxide emission a year. Gagal, faces shortage of power during winter, as hydro-power plants taper off generation due to snowing.
ACC invested Rs. 100 crore to set up the plant which is fitted with a turbine that can enhance power production to 9 MW as and when steam availability in the cement plant improves. ACC expects to recover the investment made in Gagal in four-and-a-half years with an annual saving of Rs. 22 crore.
KN Rao, Director (Energy and Environment), told Business Line the four cement plants where the heat recovery system would be installed over 3-4 years are capable of producing 30-32 MW in all, resulting in a savings of `90-100 crore a year.
Renewable energy status
“The Wadi cement plant has the world’s largest kiln and is capable of producing up to 9 MW. We are exploring various options of funding the projects,” he said.
The cement industry has urged the Government to give renewable energy status to waste-heat recovery plants. Most of the cement companies are power surplus as they have captive power plants. The surplus power produced through waste heat is sold at Rs. 2.30 a unit due to lack of renewable energy status.
A few cement plants buy grid power at Rs. 6.20 a unit, while the production cost of thermal power works out to Rs. 4.50-5 a unit. The industry with a cement production capacity of 350 million tonnes is capable of producing about 1,000 MW through waste heat recovery, said Rao. “The industry has to invest Rs. 12,000 crore to set up 1000 MW heat recovery plants. It would be viable only if the Government fixes a competitive price for the surplus power,” he said.
Apart for heat recovery plant, ACC has drawn an elaborate plan to bring down energy consumption by 5 per cent at its 10 plants by improving efficiency.
Energy saving measures
The company targets to take up energy saving measures, which call for low investment and early payback. For instance, Rao said installation of variable speed drive to control the speed of large motors used in the cement plant does not call for huge investment and the project can be completed in sa hort span, besides payback is less than a year.
Sebi-approved film investment fund to be launched soon
Mumbai: Soon, those not connected with the Hindi film segment in any way will also be able to reap the benefits of the sector’s double-digit growth, with Third Eye Cinema Fund (TCEF), a Securities and Exchange Board of India (Sebi)-registered alternative investment fund, set to hit the market.
TCEF, which will target well-heeled investors, aims to generate about 25 per cent returns.
Kewal Handa, chief executive of the fund and ex-managing director of Pfizer, says, “Given the growth of the Indian film industry, many individuals want to invest in it, but have no clue how to go about it. Also, there are many myths such as the segment isn’t professional and organised. With the digitisation of screens and the advent of a corporate structure in major studios/production houses, these myths are being busted. What better time to enter the industry and make it more professional and transparent?”
Handa and his team have already started pitching the concept to prospective investors. He is confident the first project under the new fund will be underway by the third quarter of this year.
To ensure transparency and professionalism, the fund has roped in various agencies as auditors and advisors. While IL&FS Trust Company will act as the fund’s trustees, Fidelis, the production audit agency, will oversee and keep a check on production, in terms of costs. KPMG will look after taxation and audit, while ALMT will be the fund’s legal advisor. Karvy will play the role of a registrar.
TCEF will follow the mini studio model and seek to invest in films across functions---from pre-production to distribution and marketing. Apart from co-producing and distributing Hindi films, the fund will also explore opportunities in distributing Hollywood films not backed by major Hollywood studios in India. It will also look at syndication of content across the satellite and digital platforms by acquiring the intellectual property rights (IPR) for either the entire film or just its music.
The fund’s advisory board includes directors such as Ashutosh Gowarikar, Kunal Kohli, John Mathew Mathan, Chandraprakash Dwivedi, Sagar Bellary and Nagesh Kukunoor.
Apart from Handa, the fund’s management also comprises Chief Investment Advisor Sandeep Bhargava and Chief Operating Officer Shariq Patel.
Patel says, “We will be looking at investing in films such that the money can keep circulating at a brisk pace. We understand the risk in the film business and, therefore, will invest in different films in different ways. Our interest will be in content-driven films with budgets of Rs 5-20 crore.”
While it might not be India’s first film fund, Handa is confident an approval from Sebi will stand it in better stead. “The fund will have a more professional approach to business and will undertake due diligence. It will operate in a transparent manner, with the NAV (net asset value) published every six months to show the heath of the fund, among other things,” he says.
In 2008, Religare Enterprises and Vistaar Entertainment Ventures had joined hands to start India’s first film fund, Vistaar Religare, with a size of Rs 200 crore. In 2012, DAR Media and MentorCap Management together launched the Rs 100-crore Dar MentorCap Film Fund. While DarMentorCap Film Fund had secured Sebi approval, the fund wasn’t actively involved in investing in cinema, barring co-productions under Dar Motion Pictures.
TCEF, which will target well-heeled investors, aims to generate about 25 per cent returns.
Kewal Handa, chief executive of the fund and ex-managing director of Pfizer, says, “Given the growth of the Indian film industry, many individuals want to invest in it, but have no clue how to go about it. Also, there are many myths such as the segment isn’t professional and organised. With the digitisation of screens and the advent of a corporate structure in major studios/production houses, these myths are being busted. What better time to enter the industry and make it more professional and transparent?”
Handa and his team have already started pitching the concept to prospective investors. He is confident the first project under the new fund will be underway by the third quarter of this year.
To ensure transparency and professionalism, the fund has roped in various agencies as auditors and advisors. While IL&FS Trust Company will act as the fund’s trustees, Fidelis, the production audit agency, will oversee and keep a check on production, in terms of costs. KPMG will look after taxation and audit, while ALMT will be the fund’s legal advisor. Karvy will play the role of a registrar.
TCEF will follow the mini studio model and seek to invest in films across functions---from pre-production to distribution and marketing. Apart from co-producing and distributing Hindi films, the fund will also explore opportunities in distributing Hollywood films not backed by major Hollywood studios in India. It will also look at syndication of content across the satellite and digital platforms by acquiring the intellectual property rights (IPR) for either the entire film or just its music.
The fund’s advisory board includes directors such as Ashutosh Gowarikar, Kunal Kohli, John Mathew Mathan, Chandraprakash Dwivedi, Sagar Bellary and Nagesh Kukunoor.
Apart from Handa, the fund’s management also comprises Chief Investment Advisor Sandeep Bhargava and Chief Operating Officer Shariq Patel.
Patel says, “We will be looking at investing in films such that the money can keep circulating at a brisk pace. We understand the risk in the film business and, therefore, will invest in different films in different ways. Our interest will be in content-driven films with budgets of Rs 5-20 crore.”
While it might not be India’s first film fund, Handa is confident an approval from Sebi will stand it in better stead. “The fund will have a more professional approach to business and will undertake due diligence. It will operate in a transparent manner, with the NAV (net asset value) published every six months to show the heath of the fund, among other things,” he says.
In 2008, Religare Enterprises and Vistaar Entertainment Ventures had joined hands to start India’s first film fund, Vistaar Religare, with a size of Rs 200 crore. In 2012, DAR Media and MentorCap Management together launched the Rs 100-crore Dar MentorCap Film Fund. While DarMentorCap Film Fund had secured Sebi approval, the fund wasn’t actively involved in investing in cinema, barring co-productions under Dar Motion Pictures.
TIST team invited for Mars rover design contest
Kochi: A team of five students from Kerala has been selected for an international competition in the US for designing a rover for Mars mission.
The team from Toc-H Institute of Science and Technology (TIST) is among the 31 teams selected for University Rover Challenge (URC) from six countries.
This is for the first time a team from an engineering college in Kerala is selected for competing in the URC in the US. The team will also compete in CanSaT in US organised by American Astronautical Society (AAS) and American Institute of Aeronautics & Astronautics (AIAA) in association with NASA.
While the CanSat competition will be held in Texas in June, the URC will be held at the Mars Desert Research Station (MDRS) in the remote barren desert of southern Utah in May. The URC is the world's premier robotics competition for college students.
The six countries sending teams for the competition are the US, India, Egypt, Poland, Canada and Bangladesh. The students are from prestigious institutions, including Yale University, Cornell University and the Warsaw University of Technology.
It is for the second consecutive year that a team from TIST has been selected for the CanSat.
The five members of TIST team are: Muhammed Juhaim Ibnu Abdul Jabbar, PV Abimanyu Nair, Jibin Jose, Anoop Nayak and Joseph Stephen. The team’s faculty advisors are Kiran George Varghese and Shajan K Thomas.
The team from Toc-H Institute of Science and Technology (TIST) is among the 31 teams selected for University Rover Challenge (URC) from six countries.
This is for the first time a team from an engineering college in Kerala is selected for competing in the URC in the US. The team will also compete in CanSaT in US organised by American Astronautical Society (AAS) and American Institute of Aeronautics & Astronautics (AIAA) in association with NASA.
While the CanSat competition will be held in Texas in June, the URC will be held at the Mars Desert Research Station (MDRS) in the remote barren desert of southern Utah in May. The URC is the world's premier robotics competition for college students.
The six countries sending teams for the competition are the US, India, Egypt, Poland, Canada and Bangladesh. The students are from prestigious institutions, including Yale University, Cornell University and the Warsaw University of Technology.
It is for the second consecutive year that a team from TIST has been selected for the CanSat.
The five members of TIST team are: Muhammed Juhaim Ibnu Abdul Jabbar, PV Abimanyu Nair, Jibin Jose, Anoop Nayak and Joseph Stephen. The team’s faculty advisors are Kiran George Varghese and Shajan K Thomas.
Cipla bets big on cell therapy
Mumbai: Stem cells are set to be a major branch of medical treatment, says Cipla Chairman YK Hamied. Regenerative medicine, or cell therapy, is a rapidly emerging area of biomedical research and would be an ideal supplement for existing medical treatments, he added.
Cell therapy refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury.
“We have a research unit in Malaysia that is conducting research on stem cells,” Hamied said while speaking about Stempeutics Research with which it has an alliance. The Manipal Group-promoted Stempeutics is developing stem cell-based medicinal products with facilities in Kuala Lumpur (Malaysia) and Bangalore.
“We are partners in the Bangalore company,” he said. The enormous potential of stem cells in the treatment of chronic and several incurable diseases is boosting the overall stem cells therapy market, he added.
Poised to reach an estimated $88.3 billion by 2015, the global stem cells market has been growing at a compounded annual growth rate of 14.8 per cent, driven by the increasing demand of stem cell therapy.
In India, the stem cell business is expected to touch $8 billion ( Rs. 48,880 crore today) by 2015. With three phase II clinical trials in progress in India –for critical limb Ischemia (meaning restriction in blood supply to tissues), osteoarthritis and liver cirrhosis –Stempeutics aims to bring the first product into the Indian and Malaysian markets by 2015.
Under the alliance, Cipla has invested over Rs. 50 crore in Stempeutics, with a focus on research of stem cell-based products, and has done something similar in China, where it has streamlined its investments towards its core business. The drug-maker recently exited a significant part of its investment in its Chinese partner Desano Holdings.
Despite the lack of legislation and awareness, besides quality and ethical issues that have deterred growth of the stem cell therapy business in India, the country remains the top priority for the Mumbai-based drug-maker, the Cipla Chairman told Business Line .
“India is still the best. Yes, we have units in China and conduct research in Malaysia, but we have always been very nationalist minded,” said Hamied. “We have always held that the (Indian) Government can do more for domestic companies. They should give us infrastructure, strengthen indigenous manufacturers. They should not keep pandering to multinationals.”
Cell therapy refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury.
“We have a research unit in Malaysia that is conducting research on stem cells,” Hamied said while speaking about Stempeutics Research with which it has an alliance. The Manipal Group-promoted Stempeutics is developing stem cell-based medicinal products with facilities in Kuala Lumpur (Malaysia) and Bangalore.
“We are partners in the Bangalore company,” he said. The enormous potential of stem cells in the treatment of chronic and several incurable diseases is boosting the overall stem cells therapy market, he added.
Poised to reach an estimated $88.3 billion by 2015, the global stem cells market has been growing at a compounded annual growth rate of 14.8 per cent, driven by the increasing demand of stem cell therapy.
In India, the stem cell business is expected to touch $8 billion ( Rs. 48,880 crore today) by 2015. With three phase II clinical trials in progress in India –for critical limb Ischemia (meaning restriction in blood supply to tissues), osteoarthritis and liver cirrhosis –Stempeutics aims to bring the first product into the Indian and Malaysian markets by 2015.
Under the alliance, Cipla has invested over Rs. 50 crore in Stempeutics, with a focus on research of stem cell-based products, and has done something similar in China, where it has streamlined its investments towards its core business. The drug-maker recently exited a significant part of its investment in its Chinese partner Desano Holdings.
Despite the lack of legislation and awareness, besides quality and ethical issues that have deterred growth of the stem cell therapy business in India, the country remains the top priority for the Mumbai-based drug-maker, the Cipla Chairman told Business Line .
“India is still the best. Yes, we have units in China and conduct research in Malaysia, but we have always been very nationalist minded,” said Hamied. “We have always held that the (Indian) Government can do more for domestic companies. They should give us infrastructure, strengthen indigenous manufacturers. They should not keep pandering to multinationals.”
Swiss firm Galderma eyes India skincare, beauty market
New Delhi: Galderma, a Switzerland-based pharmaceutical company, owned by food and beverage giant Nestle, plans to tap the Rs 30,000-crore skincare and beauty market in India.
At present, it sells a little over 30 prescription-based medicines in the dermatology segment. It is now foraying into the anti-ageing injectible and over-the-counter (OTC) segments. It has introduced three to four products in the aesthetic and corrective segment, including its range of Restylane vital skin boosters. It plans at least 12 more products in the segment by 2017, of which eight would be launched this year, said Madhusudhan H K, head of the aesthetic and corrective business in India.
“There are a lot of new trends driving this business in India. We want to encash this opportunity by helping the consumer with more options,” he said. He added the aesthetic and corrective business will be primarily focused on injectibles, as there was huge space, with demand for dermal fillers and other aesthetic treatments increasing rapidly in the country.
The company is also expected to launch an OTC skin care business and has identified five specific brands for launche within the next two years.
Galderma is targeting a five-fold growth in annual sales to Rs 500 crore by 2018 in its dermatology business here. The company has manufacturing facilities in the US and France; it mostly imports its products for India. Lausanne-based Galderma was founded as a 50:50 venture of Nestle and L’Oreal. Last month, Nestle bought the other 50 per cent. Galderma is in India for 11 years. It has added acne and skin cancer treatments to Nestle’s health care product line, which includes nutrition drink brands such as Boost and some soluble fibre supplements.
To have a firm footing in the anti-ageing injectible market, Galderma has started academies in Mumbai and New Delhi to train doctors in aesthetic medicine delivery.
The idea is to create a market and standard treatment protocols for the Indian face. According to Madhusudhan, the aesthetic and corrective business in India is still in a nascent stage; Allergan is the only other established entity in the organised segment. However, there are various unorganised distributors of such products. It is seen growing rapidly, at 30-35 per cent a year.
He said the number of practitioners in India is low. “In India, there are only 800 doctors who are practising aesthetic medicine, as compared to 6,000 in Korea. So, there is a huge opportunity which we can tap,” he said.
At present, it sells a little over 30 prescription-based medicines in the dermatology segment. It is now foraying into the anti-ageing injectible and over-the-counter (OTC) segments. It has introduced three to four products in the aesthetic and corrective segment, including its range of Restylane vital skin boosters. It plans at least 12 more products in the segment by 2017, of which eight would be launched this year, said Madhusudhan H K, head of the aesthetic and corrective business in India.
“There are a lot of new trends driving this business in India. We want to encash this opportunity by helping the consumer with more options,” he said. He added the aesthetic and corrective business will be primarily focused on injectibles, as there was huge space, with demand for dermal fillers and other aesthetic treatments increasing rapidly in the country.
The company is also expected to launch an OTC skin care business and has identified five specific brands for launche within the next two years.
Galderma is targeting a five-fold growth in annual sales to Rs 500 crore by 2018 in its dermatology business here. The company has manufacturing facilities in the US and France; it mostly imports its products for India. Lausanne-based Galderma was founded as a 50:50 venture of Nestle and L’Oreal. Last month, Nestle bought the other 50 per cent. Galderma is in India for 11 years. It has added acne and skin cancer treatments to Nestle’s health care product line, which includes nutrition drink brands such as Boost and some soluble fibre supplements.
To have a firm footing in the anti-ageing injectible market, Galderma has started academies in Mumbai and New Delhi to train doctors in aesthetic medicine delivery.
The idea is to create a market and standard treatment protocols for the Indian face. According to Madhusudhan, the aesthetic and corrective business in India is still in a nascent stage; Allergan is the only other established entity in the organised segment. However, there are various unorganised distributors of such products. It is seen growing rapidly, at 30-35 per cent a year.
He said the number of practitioners in India is low. “In India, there are only 800 doctors who are practising aesthetic medicine, as compared to 6,000 in Korea. So, there is a huge opportunity which we can tap,” he said.
AirAsia India receives first A320
Chennai: AirAsia India received its first aircraft, a brand new Airbus A320, at the Chennai airport on Saturday .
The 180-seater all-economy configuration aircraft takes AirAsia India closer to launching its low cost service in the domestic sector.
According to a press release from AirAsia, the A320 from Airbus’ factory in Toulouse, France, was received with a ‘water cannon salute’ as it taxied down the runway.
AirAsia India is awaiting an air operating permit to start flying commercially. AirAsia’s CEO Tony Fernandes recently told a wire agency that AirAsia India was likely to start operations in March or April.
AirAsia India has got in-principle approval to import ten Airbus A320 aircraft.ý It has partnered with the Tata group and the Arun Bhatia-led Telstra Tradeplace to run the low-cost passenger airline service in the country. The joint venture partners announced the start of the new airline in February 2013.
Mittu Chandilya, CEO, AirAsia India, in a statement said, “The arrival of our first A320 signifies that we are a step closer to our dream to create a new benchmark in the low-cost air travel category.”
AirAsia India’s fleet will be drawn from the 475 A320 family aircraft ordered by the AirAsia Group. To date, almost a third of the aircraft on order have already been delivered and are flying on AirAsia Group’s operations out of Kuala Lumpur, Bangkok, Jakarta, Manila and now Chennai, said a company release.
The 180-seater all-economy configuration aircraft takes AirAsia India closer to launching its low cost service in the domestic sector.
According to a press release from AirAsia, the A320 from Airbus’ factory in Toulouse, France, was received with a ‘water cannon salute’ as it taxied down the runway.
AirAsia India is awaiting an air operating permit to start flying commercially. AirAsia’s CEO Tony Fernandes recently told a wire agency that AirAsia India was likely to start operations in March or April.
AirAsia India has got in-principle approval to import ten Airbus A320 aircraft.ý It has partnered with the Tata group and the Arun Bhatia-led Telstra Tradeplace to run the low-cost passenger airline service in the country. The joint venture partners announced the start of the new airline in February 2013.
Mittu Chandilya, CEO, AirAsia India, in a statement said, “The arrival of our first A320 signifies that we are a step closer to our dream to create a new benchmark in the low-cost air travel category.”
AirAsia India’s fleet will be drawn from the 475 A320 family aircraft ordered by the AirAsia Group. To date, almost a third of the aircraft on order have already been delivered and are flying on AirAsia Group’s operations out of Kuala Lumpur, Bangkok, Jakarta, Manila and now Chennai, said a company release.
Engineers India Ltd bags contract in $3.6 billion Oman plastics project
New Delhi: Oman Oil Refineries and Petroleum Industries Company (Orpic) has awarded a pie of its $3.6 billion project to Engineers India Ltd, recognizing the Indian state-run engineering consultancy provider's prowess.
EIL has won the PMC (project management consultancy) contract for Orpic's Liwa Plastics Project at Sohar in Oman against international competitive bidding. The contract is valued at over $40 million and signifies the company's steady headway overseas.
EIL's contract is one of the two major awards announced by Orpic, which gave the front end engineering and design contract to Chicago Bridge & Iron Company (CB & I) operating out of The Hague, Netherlands .
Orpic is owned by the government of Oman and Oman Oil Company SAOC, the commercial company wholly owned by the government created investment in the energy sector.
Liwa Plastics Project consists of a new petrochemical complex adjacent to the Sohar Refinery. The feedstock for the plant is to be brought from Fahud, 300 km from Sohar. EIL's contract also includes a feedstock extraction plant in Fahud and its transportation facility to Sohar.
EIL has won the PMC (project management consultancy) contract for Orpic's Liwa Plastics Project at Sohar in Oman against international competitive bidding. The contract is valued at over $40 million and signifies the company's steady headway overseas.
EIL's contract is one of the two major awards announced by Orpic, which gave the front end engineering and design contract to Chicago Bridge & Iron Company (CB & I) operating out of The Hague, Netherlands .
Orpic is owned by the government of Oman and Oman Oil Company SAOC, the commercial company wholly owned by the government created investment in the energy sector.
Liwa Plastics Project consists of a new petrochemical complex adjacent to the Sohar Refinery. The feedstock for the plant is to be brought from Fahud, 300 km from Sohar. EIL's contract also includes a feedstock extraction plant in Fahud and its transportation facility to Sohar.
Kassia inks MoU with Karachi Chamber
Bangalore: Karnataka Small Scale Industries Association (Kassia) and Karachi Chamber of Commerce and Industry (KCCI) have signed an MoU to explore trade development through their institutional members.
The MoU was signed by Mumammad Idrees, Vice-President, Karachi Chamber of Commerce and Industry and BP Shashidhar, President, Kassia.
Earlier on Friday, the Federation of Indian Micro and Small and Medium Enterprises (FISME) and Kassia jointly organised a seminar on trade opportunities between India and Pakistan at Kassia Udyog Bhavan here.
Addressing the meet, Ravi Kumar, Senior Zonal Manager, NSIC, told the Pakistani delegation that NSIC had signed MoUs with nearly 30 countries and was open to doing the same with Pakistan too once the two countries signed the FTA (free trade agreement).
He hoped that India and Pakistan would move swiftly towards signing the FTA. Shashidhar said the MSME sector in Karnataka contributed 40 per cent of exports to 80 countries, comprising a whole range of engineering items.
Mohan Suresh, former president, FISME, pleaded for signing of trade agreements between India and Pakistan.
A 16-Member industry delegation comprising representatives of the Federation of Pakistan Chambers of Commerce and Industry (FPCCI), Karachi Chamber of Commerce and Industry (KCCI), Lahore Chamber of Commerce, Islamabad Chamber of Commerce, Islamabad Women Chamber of Commerce and All Pakistan Furniture Makers Association took part in the seminar.
The delegation represented industrialists from various sectors
The MoU was signed by Mumammad Idrees, Vice-President, Karachi Chamber of Commerce and Industry and BP Shashidhar, President, Kassia.
Earlier on Friday, the Federation of Indian Micro and Small and Medium Enterprises (FISME) and Kassia jointly organised a seminar on trade opportunities between India and Pakistan at Kassia Udyog Bhavan here.
Addressing the meet, Ravi Kumar, Senior Zonal Manager, NSIC, told the Pakistani delegation that NSIC had signed MoUs with nearly 30 countries and was open to doing the same with Pakistan too once the two countries signed the FTA (free trade agreement).
He hoped that India and Pakistan would move swiftly towards signing the FTA. Shashidhar said the MSME sector in Karnataka contributed 40 per cent of exports to 80 countries, comprising a whole range of engineering items.
Mohan Suresh, former president, FISME, pleaded for signing of trade agreements between India and Pakistan.
A 16-Member industry delegation comprising representatives of the Federation of Pakistan Chambers of Commerce and Industry (FPCCI), Karachi Chamber of Commerce and Industry (KCCI), Lahore Chamber of Commerce, Islamabad Chamber of Commerce, Islamabad Women Chamber of Commerce and All Pakistan Furniture Makers Association took part in the seminar.
The delegation represented industrialists from various sectors
Ibibo buys 51% stake in YourBus.com
Mumbai: Online travel company Ibibo Group, that owns portals such as Goibibo.com, redBus.in and Travelboutique has acquired 51 per cent stake in online bus tracking and analytics platform YourBus.com for an undisclosed amount.
With this Ibibo is all set to achieve a leadership position in the online travel space that has players such as Makemytrip.com, Yatra.com, Cleartrip, Ixigo and Akbar Travels.
Ibibo, which is owned by South Africa based Naspers, had acquired RedBus for Rs 780 crore last year.
Ashish Kashyap, CEO of ibiboGroup, said: “Our key motivation to acquire YourBus is to enhance passenger experience at redBus.in and Goibibo.com, whilst at the same time providing additional technologies and analytics to the Bus operators so as to increase their efficiencies in the marketplace. ”
IbiboGroup will integrate the YourBus platform with both its existing online travel properties, redBus.in and Goibibo.com. Following this YourBus founders Rajesh Mallipeddi and Satya Padmanabham will work closely with the RedBus team. YourBus is functional in 200 buses and is already integrated with redBus’ mobile and web applications. The acquisition will enable the YourBus team to expand its reach potentially to thousands of buses.
Founded in 2011, Yourbus is a GPS-based tracking platform, which solves problems for both bus travelers and bus operators. Bus travelers can access real time information regarding the location of a bus on their mobiles as well as online. Furthermore, important information such as bus delays and time of departure is pushed to passengers via both SMS and web notifications.
Bus operators are able to track their buses and get detailed analytics on punctuality and efficiency of their buses. They can sort this information by route, bus driver and vehicle number and also get estimated time of arrival reports and other weekly /daily location based reports.
With this Ibibo is all set to achieve a leadership position in the online travel space that has players such as Makemytrip.com, Yatra.com, Cleartrip, Ixigo and Akbar Travels.
Ibibo, which is owned by South Africa based Naspers, had acquired RedBus for Rs 780 crore last year.
Ashish Kashyap, CEO of ibiboGroup, said: “Our key motivation to acquire YourBus is to enhance passenger experience at redBus.in and Goibibo.com, whilst at the same time providing additional technologies and analytics to the Bus operators so as to increase their efficiencies in the marketplace. ”
IbiboGroup will integrate the YourBus platform with both its existing online travel properties, redBus.in and Goibibo.com. Following this YourBus founders Rajesh Mallipeddi and Satya Padmanabham will work closely with the RedBus team. YourBus is functional in 200 buses and is already integrated with redBus’ mobile and web applications. The acquisition will enable the YourBus team to expand its reach potentially to thousands of buses.
Founded in 2011, Yourbus is a GPS-based tracking platform, which solves problems for both bus travelers and bus operators. Bus travelers can access real time information regarding the location of a bus on their mobiles as well as online. Furthermore, important information such as bus delays and time of departure is pushed to passengers via both SMS and web notifications.
Bus operators are able to track their buses and get detailed analytics on punctuality and efficiency of their buses. They can sort this information by route, bus driver and vehicle number and also get estimated time of arrival reports and other weekly /daily location based reports.
Subscribe to:
Posts (Atom)